Loading
Latest filing published 13 Mar 2026 for ONCOLYTICS BIOTECH INC, €4,200.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jared Kelly discloses dealings in Oncolytics Biotech Inc to SEC (Form 4). Between 11 February 2026 and 12 March 2026, the trades on record add up to 3 filings.
The open-market record is one-sided, with 3 purchases worth €29k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
A typical purchase (the median) is worth €4,200. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -13.3%. These figures describe past trades and do not predict future prices.
The newest entry dates from 13 March 2026: an open-market purchase of €4,200, in Oncolytics Biotech Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations